作者
Ana Montalban-Arques,Egle Katkeviciutė,Philipp Busenhart,Anna Bircher,Jakob Wirbel,Georg Zeller,Yasser Morsy,Lubor Borsig,Jesus F. Glaus Garzon,Anne Müller,Isabelle C. Arnold,Mariela Artola-Borán,Michael Krauthammer,Anna Sintsova,Nicola Zamboni,Gabriel E. Leventhal,Laura Berchtold,Tomás de Wouters,Gerhard Rogler,Katharina Baebler,Marlene Schwarzfischer,Larissa Hering,Iván Olivares-Rivas,Kirstin Atrott,Claudia Gottier,Silvia Lang,Onur Boyman,Ralph Fritsch,Markus G. Manz,Marianne R. Spalinger,Michael Scharl
摘要
Despite overall success, T cell checkpoint inhibitors for cancer treatment are still only efficient in a minority of patients. Recently, intestinal microbiota was found to critically modulate anti-cancer immunity and therapy response. Here, we identify Clostridiales members of the gut microbiota associated with a lower tumor burden in mouse models of colorectal cancer (CRC). Interestingly, these commensal species are also significantly reduced in CRC patients compared with healthy controls. Oral application of a mix of four Clostridiales strains (CC4) in mice prevented and even successfully treated CRC as stand-alone therapy. This effect depended on intratumoral infiltration and activation of CD8+ T cells. Single application of Roseburia intestinalis or Anaerostipes caccae was even more effective than CC4. In a direct comparison, the CC4 mix supplementation outperformed anti-PD-1 therapy in mouse models of CRC and melanoma. Our findings provide a strong preclinical foundation for exploring gut bacteria as novel stand-alone therapy against solid tumors.